Progyny, Inc. (NASDAQ:PGNY) Given Consensus Rating of "Hold" by Brokerages

Progyny, Inc. (NASDAQ:PGNY - Get Free Report) has been assigned a consensus rating of "Hold" from the twelve analysts that are covering the stock, MarketBeat.com reports. Seven analysts have rated the stock with a hold rating and five have issued a buy rating on the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $23.64.

A number of equities analysts have recently issued reports on PGNY shares. JPMorgan Chase & Co. upped their target price on shares of Progyny from $17.00 to $23.00 and gave the stock a "neutral" rating in a research report on Tuesday, January 28th. BTIG Research upgraded Progyny from a "neutral" rating to a "buy" rating and set a $28.00 price target on the stock in a report on Monday, March 31st. Canaccord Genuity Group boosted their price objective on Progyny from $17.00 to $23.00 and gave the stock a "hold" rating in a report on Friday, February 28th. Finally, Bank of America lifted their price target on shares of Progyny from $21.00 to $25.00 and gave the stock a "buy" rating in a research report on Tuesday, February 11th.

Progyny Stock Performance

Progyny stock traded down $2.17 during trading hours on Friday, hitting $21.20. 3,566,405 shares of the stock were exchanged, compared to its average volume of 1,722,248. The stock has a market capitalization of $1.82 billion, a P/E ratio of 36.55, a P/E/G ratio of 2.39 and a beta of 1.37. The business's 50-day moving average is $21.95 and its two-hundred day moving average is $19.56. Progyny has a 12 month low of $13.39 and a 12 month high of $30.42.

Progyny (NASDAQ:PGNY - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The company reported $0.17 earnings per share for the quarter, missing analysts' consensus estimates of $0.45 by ($0.28). The business had revenue of $324.04 million for the quarter, compared to analyst estimates of $307.86 million. Progyny had a net margin of 5.03% and a return on equity of 11.36%. The company's revenue for the quarter was up 16.5% on a year-over-year basis. During the same period in the prior year, the business earned $0.17 earnings per share. On average, equities analysts predict that Progyny will post 0.6 earnings per share for the current fiscal year.

Institutional Trading of Progyny

A number of large investors have recently bought and sold shares of the business. Signaturefd LLC raised its holdings in shares of Progyny by 1,355.0% during the fourth quarter. Signaturefd LLC now owns 1,455 shares of the company's stock worth $25,000 after acquiring an additional 1,355 shares during the period. GAMMA Investing LLC boosted its position in shares of Progyny by 341.4% during the fourth quarter. GAMMA Investing LLC now owns 1,611 shares of the company's stock worth $28,000 after buying an additional 1,246 shares during the period. Nisa Investment Advisors LLC grew its holdings in shares of Progyny by 108.4% during the fourth quarter. Nisa Investment Advisors LLC now owns 2,934 shares of the company's stock worth $51,000 after buying an additional 1,526 shares in the last quarter. Caitlin John LLC lifted its stake in Progyny by 2,974.8% in the 4th quarter. Caitlin John LLC now owns 3,290 shares of the company's stock valued at $57,000 after acquiring an additional 3,183 shares in the last quarter. Finally, Natixis acquired a new position in Progyny during the 4th quarter worth approximately $69,000. 94.93% of the stock is owned by institutional investors.

About Progyny

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.